Oscient Pharmaceuticals Corp. (OSCI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oscient Pharmaceuticals Corp. (OSCI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: OldAIMGuy who wrote (451)	1/14/1999 12:18:00 AM
From: Ron	Read Replies (2) of 1154

Interesting GENE news today. Think it will have any effect? WALTHAM, Mass., Jan. 13 /PRNewswire/ -- Genome Therapeutics Corp. (Nasdaq: GENE) and Astra AB (NYSE: A) today announced the first ever comparison of two complete genomic sequences of a single bacterium, Helicobacter pylori, a common pathogen shown to cause a variety of conditions including gastritis, peptic ulcers and is also known to be associated with certain forms of stomach cancer. The genomic comparison, published in the January 14 issue of Nature, provides fundamental new insights into variance in H. pylori's genetic structure, greatly simplifying the designation of targets for new drugs and vaccines. The research, which was conducted primarily by scientists at Genome Therapeutics and Astra Research Center Boston, is directed toward the discovery of novel treatments to battle H. pylori infections.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next